Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

References

Page 1

	Year	Citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, New England Journal of Medicine	2004	11.4K
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, New England Journal of Medicine	2009	8.2K
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, New England Journal of Medicine	2010	5.5K
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Rafael Rosell, Enric Carcereny, Radj Gervais, The Lancet Oncology OncologyStandard ChemotherapyRandomised Phase 3PathologyBronchial Neoplasm	2012	5.5K
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Caicun Zhou, Yi‐Long Wu, Gongyan Chen, The Lancet Oncology MedicinePathologyBronchial NeoplasmFirst-line TreatmentCancer Treatment	2011	4K
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain William Pao, Vincent A. Miller, Katerina Politi, PLoS Medicine	2005	3.5K
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Journal of Clinical Oncology	2013	3.2K
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Yi‐Long Wu, Caicun Zhou, Chengping Hu, The Lancet Oncology Lux-lung 6MedicineRandomised Phase 3PathologyBronchial Neoplasm	2014	2K
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, The Lancet Oncology Lux-lung 3Lux-lung 6MedicinePathologyBronchial Neoplasm	2015	1.6K
Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence Tetsuya Mitsudomi, Takayuki Kosaka, Hideki Endoh, Journal of Clinical Oncology	2005	956

Page 1